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The syndromes caused by frontotemporal lobar degeneration have highly heterogeneous and overlapping clinical features. There has
been great progress in the refinement of clinical diagnostic criteria in the past decade, but we propose that a better understanding of
aetiology, pathophysiology and symptomatic treatments can arise from a transdiagnostic approach to clinical phenotype and brain
morphometry. In a cross-sectional epidemiological study, we examined 310 patients with a syndrome likely to be caused by fronto-
temporal lobar degeneration, including behavioural variant frontotemporal dementia, non-fluent, and semantic variants of primary
progressive aphasia (PPA), progressive supranuclear palsy and corticobasal syndrome. We included patients with logopenic PPA and
those who met criteria for PPA but not a specific subtype. To date, 49 patients have a neuropathological diagnosis. A principal com-
ponent analysis identified symptom dimensions that broadly recapitulated the core features of the main clinical syndromes. However,
the subject-specific scores on these dimensions showed considerable overlap across the diagnostic groups. Sixty-two per cent of partici-
pants had phenotypic features that met the diagnostic criteria for more than one syndrome. Behavioural disturbance was prevalent in
all groups. Forty-four per cent of patients with corticobasal syndrome had progressive supranuclear palsy-like features and 30% of
patients with progressive supranuclear palsy had corticobasal syndrome-like features. Many patients with progressive supranuclear
palsy and corticobasal syndrome had language impairments consistent with non-fluent variant PPA while patients with behavioural
variant frontotemporal dementia often had semantic impairments. Using multivariate source-based morphometry on a subset of
patients (n = 133), we identified patterns of covarying brain atrophy that were represented across the diagnostic groups. Canonical
correlation analysis of clinical and imaging components found three key brain-behaviour relationships, with a continuous spectrum
across the cohort rather than discrete diagnostic entities. In the 46 patients with follow-up (mean 3.6 years) syndromic overlap
increased with time. Together, these results show that syndromes associated with frontotemporal lobar degeneration do not form dis-
crete mutually exclusive categories from their clinical features or structural brain changes, but instead exist in a multidimensional spec-
trum. Patients often manifest diagnostic features of multiple disorders while deficits in behaviour, movement and language domains
are not confined to specific diagnostic groups. It is important to recognize individual differences in clinical phenotype, both for clinical
management and to understand pathogenic mechanisms. We suggest that a transdiagnostic approach to the spectrum of frontotempo-
ral lobar degeneration syndromes provides a useful framework with which to understand disease aetiology, progression, and hetero-
geneity and to target future treatments to a higher proportion of patients.
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Introduction
The clinical disorders caused by frontotemporal lobar degen-
eration pathologies (FTLD) are highly heterogeneous in their
pathology and phenotypes (Kertesz et al., 2005; MacKenzie
et al., 2010; Rohrer et al., 2011). Patients are typically diag-
nosed as having one of several principal syndromes, including
behavioural variant frontotemporal dementia (bvFTD)
(Rascovsky et al., 2011), primary progressive aphasia [with
the non-fluent (nfvPPA) and semantic (svPPA) subtypes]
(Gorno-Tempini et al., 2011), progressive supranuclear palsy
(PSP) (Ho¨glinger et al., 2017) or corticobasal syndrome (CBS)
(Armstrong et al., 2013). The clinicopathological correlations
of these syndromes are imprecise (Irwin et al., 2015). For ex-
ample, bvFTD can be associated with tau, TDP-43, FUS pro-
tein inclusions or mixed neuropathology (Perry et al., 2017).
Some clinical syndromes, such as PSP-Richardson’s syndrome,
have good correlation with the associated pathology (Gazzina
et al., 2019); however, the corresponding pathology may
have diverse phenotypic expressions (Respondek et al., 2014).
Recent revisions of diagnostic criteria recognize this hetero-
geneity (Armstrong et al., 2013; Ho¨glinger et al., 2017), and
there may be future improvements in clinicopathological cor-
relations by imaging or fluid-based biomarkers, aiming to op-
timize patient selection for disease-modifying therapies (Irwin
et al., 2015; Meeter et al., 2017).
Here we propose that the effort to refine diagnostic segre-
gation of the disorders has fundamental limitations. These
are not merely due to the limits of a given test or biomarker
but are biologically real constraints that can in turn be in-
formative about the nature of the disorders. We suggest that
a better understanding of aetiology and pathophysiology,
and more effective therapies, can be gained by examining
the phenotypic patterns across the broad spectrum of all
FTLD-associated disease. Symptomatic therapies may espe-
cially benefit from such a transdiagnostic approach, selecting
patients based on the presence of relevant clinical features,
whichever their diagnostic label or proteinopathy.
A transdiagnostic approach is increasingly used in psych-
iatry, epitomized by the Research Domain Criteria method-
ology (Kozak and Cuthbert, 2016; Grisanzio et al., 2018). A
similar approach is applicable to neurodegenerative diseases
with overlapping phenotypes (Lambon Ralph et al., 2003;
Husain, 2017) and cognitive deficits after stroke (Butler
et al., 2014; Mirman et al., 2015; Halai et al., 2017). There
are many overlapping symptoms and indistinct phenotypic
boundaries between FTLD syndromes (Kertesz et al., 1999,
2005). For example, executive dysfunction is a common cog-
nitive impairment across FTLD-associated syndromes
(Burrell et al., 2014; Ranasinghe et al., 2016a) and changes
in behaviour, social cognition and personality, while charac-
teristic of bvFTD, are also seen in PSP (Cordato et al., 2005;
Ghosh et al., 2012; Gerstenecker et al., 2013), CBS (Huey
et al., 2009) and the primary progressive aphasias (Rosen
et al., 2006; Rohrer and Warren, 2010). Neuropsychiatric
symptoms, including apathy and impulsivity, occur in multiple
FTLD syndromes (Rohrer et al., 2010a; Lansdall et al., 2017).
The movement disorders typical of PSP and CBS can also de-
velop in patients diagnosed with bvFTD (Park et al., 2017)
and nfvPPA (Santos-Santos et al., 2016). Language impair-
ments are seen across all FTLD syndromes, including bvFTD
(Hardy et al., 2015), PSP and CBS (Peterson et al., 2019).
We therefore used a transdiagnostic approach to assess
the phenotype of FTLD syndromes. We tested the hypothesis
that syndromes associated with FTLD are multidimensional
clinical spectra, rather than discrete clinical entities. The col-
our map in Fig. 1A symbolizes the current most widely used
approach, in which patients have a distinct clinical pheno-
type of a singular syndrome, represented by a discrete colour
patch (‘red bvFTD’ is distinct from ‘blue PSP’) (Butler et al.,
2014). Our alternate hypothesis is that patients lie in a con-
tinuous colour-space, as shown in Fig. 1B. Intermediate or
mixed phenotypes, such as PSP-frontal (PSP-F), CBS-NAV
or svPPA with prominent behavioural disturbance, are read-
ily placed within the continuous phenotypic space. A corol-
lary hypothesis is that the multivariate clinical spectrum of
the disorders can be mapped to multivariate regional struc-
tural brain change. Note that this is not an argument for
‘lumping’ patients into super-ordinate diagnostic groups, or
for ‘splitting’ diagnoses into ever finer subtypes. This type of
transdiagnostic approach recognizes the clear individual dif-
ferences across patients and does not propose an unstruc-
tured pool; instead, the key hypothesis is that the underlying
variations in FLTD reflect a statistical structure in the form
of multiple graded dimensions rather than mutually exclu-
sive categories. Thus, the concept of phenotypic spectra
allows for both the recognition of broad similarities and
unique combinations of features.
To test our hypotheses, we exploited the epidemiologi-
cally-based Pick’s disease and Progressive Supranuclear Palsy
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Prevalence and Incidence (PiPPIN) study dataset (Coyle-
Gilchrist et al., 2016) and a replication dataset acquired 4
years later. We undertook a systematic behavioural, cogni-
tive and imaging assessment of patients with syndromes
associated with FTLD, in a region of 1.75 million people in
the UK. We predicted that while classical syndromes of
bvFTD, PPA, PSP and CBS exist, a data-driven approach
would reveal phenotypic continuity without clear separation
between phenotypes. With longitudinal follow-up of a subset
of participants, we tested the hypothesis that clinical pheno-
types merge by addition of features, with increasing over-
lap—analogous to the move towards the centre of the
colour-space. Moreover, we predicted that clusters of symp-
toms would be associated with a specific pattern of brain at-
rophy, while the extent to which a patient has this atrophy
pattern determines the severity of the associated symptoms.
Materials and methods
The rapidly evolving field of FTLD/FTD/PSP research can result
in confusion in definitions and diagnostic labels. In this paper
we use the current consensus nosology for clinical and patho-
logical diagnoses. We use FTLD to refer to the pathology, sub-
typing to tau or TDP43 pathologies where applicable. The
phrase ‘FTLD syndromes’ refers collectively to the clinical diag-
noses of bvFTD (with or without motor neuron disease), PPA,
nfvPPA, svPPA, PSP or CBS and their intermediate phenotypes.
The term ‘corticobasal degeneration’ is limited to the pathology,
while CBS refers to the clinical syndrome. Note that not all
patients will have FTLD pathology (especially lvPPA and mixed
PPA patients) and not all those with FTLD pathology will have
had one of the corresponding syndromes.
Participant recruitment
The PiPPIN study sought to recruit all patients with a clinical
diagnosis of a FTLD syndrome living in the counties of
Cambridgeshire and Norfolk in the UK. Cross-sectional assess-
ments were performed during two 24-month periods, from 1
January 2013 to 31 December 2014 and again from 1 January
2017 to 31 December 2018. Participants were recruited via mul-
tiple routes, including specialist cognitive and movement dis-
order clinics at tertiary and secondary healthcare services (using
paper and electronic health records), patient support groups
(FTD support group, PSP Association), advertisements in local
newspapers and through local research databases and the
National Institute for Health Research ‘Join Dementia Research’
registry. Patients were recruited at all stages of symptomatic dis-
ease. We sought to assess all participants, either at our research
centre or at their home or care home. Patients alive during both
study periods were invited to assessment in both periods, but
only their first visit was used for the cross-sectional analysis.
Three hundred and sixty-five patients were identified in the
catchment area, 310 of whom were met in person by the study
team for phenotypic assessment. Death or end-stage disease
Figure 1 The FTLD syndrome spectrum. (A) Schematic of current diagnostic criteria. (B) Schematic to highlight our hypothesis that FTLD
syndromes occur on a spectrum. (C and D) Four-way Venn diagrams of overlap between FTLD syndromes in the study. The numbers in each
oval refer to the number of patients who met the diagnostic criteria for those syndromes. Many patients met the diagnostic criteria for two or
more syndromes. (C) Overlap between bvFTD, nfvPPA, PSP and CBS. (D) Overlap between bvFTD, nfvPPA, svPPA and lvPPA.
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were the main reasons for our not assessing the remaining 55
cases. All participants provided written informed consent or, if
they lacked capacity to consent, their next of kin was consulted
using the ‘personal consultee’ process established by UK law.
The study had ethical approval from the Cambridge Central
Research Ethics Committee (REC 12/EE/0475).
Clinical assessment
We used a structured clinical assessment to record the presence
or absence of symptoms and signs typically seen in FTLD syn-
dromes, including all clinical features in the current consensus
diagnostic criteria (Supplementary material) (Rascovsky et al.,
2007; Bensimon et al., 2009; Gorno-Tempini et al., 2011;
Armstrong et al., 2013; Ho¨glinger et al., 2017). Each patient’s
primary diagnosis was made according to these criteria, with ref-
erence to the dominant features at the time of presentation and
assessment. Patients with a mixed PPA, who met the diagnostic
criteria for PPA but not one of the three subtypes (Gorno-
Tempini et al., 2011) were grouped with lvPPA for this study, in
view of the low numbers and the association of both phenotypes
with Alzheimer’s pathology (Sajjadi et al., 2012). For patients
who met several sub-diagnostic criteria we grouped ‘probable’
and ‘possible’ diagnoses together, and classified by the dominant
phenotype or formal MAX rules where available (Grimm et al.,
2019). We reapplied the other diagnostic criteria to each patient
to assess if he or she met the diagnostic criteria for any of the
other FTLD syndromes (excepting the ‘mutual exclusivity’ clause
included in several criteria). Patients completed the
Addenbrooke’s Cognitive Examination-Revised (ACE-R) wher-
ever possible (Mioshi et al., 2006) and a carer’s assessment was
obtained using the Cambridge Behavioural Inventory (CBI-R)
(Wear et al., 2008). At the time of writing, 49 participants have
undergone post-mortem examination, via the Cambridge Brain
Bank.
Imaging analysis
One hundred and thirty-three patients (bvFTD n = 28, nfvPPA
n = 15, svPPA n = 5 PPA n = 10, PSP n = 53, CBS n = 22) from
the phenotyped cohort were scanned at the Wolfson Brain
Imaging Centre, University of Cambridge on a Siemens 3T sys-
tem. Structural MRI was performed using a T1-weighted mag-
netization-prepared rapid acquisition gradient echo (MPRAGE)
sequence. Images were preprocessed using SPM12 with default
settings. Grey and white matter segments were combined to
whole brain images for further analysis. The DARTEL pipeline
was used to create a study-specific template using all images.
Age and total intracranial volume were included in a multiple
regression and regressed out of the data. Source-based morph-
ometry was used on the residual images to identify covarying
networks of grey and white matter atrophy, further details of
this step are given in the next section.
Statistical analysis
Figure 2 summarizes the analysis pipeline. First, we examined
the relationships between individual clinical features using dis-
tance measures and multidimensional scaling (Shepard, 1980)
(Fig. 3). The pairwise Jaccard’s distances between clinical fea-
tures were calculated, resulting in a dissimilarity matrix. Non-
classical two-dimensional scaling was performed on this dissimi-
larity matrix (Shepard, 1980).
Second, we examined patterns of covariation in clinical fea-
tures (Perry et al., 2017; Grisanzio et al., 2018; Schumacher
et al., 2019). To reduce the dimensionality of the dataset, we
grouped the presence of clinical symptoms and signs into 25
groups by summing the number of features present in each
group. Clinical feature groups were defined a priori as those
that were very closely related or were grouped together in the
diagnostic criteria. For example, we grouped apathy and inertia
into an ‘apathy’ feature group. A full list of clinical symptoms
and signs and their groupings are provided in the
Supplementary material. The clinical feature group scores, ACE-
R and CBI-R results were standardized into z-scores then
entered into a principal component analysis (PCA). A Kaiser-
Meyer-Olkin test determined the suitability of our dataset for
PCA. We selected six components using Cattell’s criteria then
performed varimax rotation.
Third, we characterized patterns of covariation in grey and
white matter atrophy across all participants. We used GIFT soft-
ware to perform source-based morphometry, a multivariate al-
ternative to voxel-based morphometry, which uses independent
component analysis (Xu et al., 2009). Source-based morphom-
etry was performed on the preprocessed images (see ‘Imaging
analysis’ section for details). We extracted 15 independent com-
ponents of covarying brain atrophy (Fig. 5), and confirmed their
reliability using ICASSO with 100 repetitions (Himberg et al.,
2004).
Fourth, we examined the relationship between clinical pheno-
type and brain atrophy (Fig. 6). We used canonical correlation
analysis (CCA) to relate the six principal components of clinical
features (Fig. 4) and the 15 imaging components (Fig. 5)
(Tsvetanov et al., 2018). All inputs were standardized into z-
scores before CCA. Pearson’s correlations were corrected for
multiple comparisons using the false discovery rate (mafdr func-
tion in MATLAB 2018b).
Finally, we examined longitudinal change in clinical feature
component scores in 46 patients who were reviewed twice. We
converted follow-up scores into z-scores based on the baseline
data, by matching each score to the respective baseline z-score.
This ensured that follow-up values were comparable to the base-
line (cross-sectional) dataset. We multiplied these standardized
follow-up z-scores by the baseline principal component coeffi-
cients to estimate follow-up principal component scores.
All patients had a clinical phenotypic assessment but other meas-
ures (including ACE-R and CBI-R) were subject to missing data.
Missing data (6.32% of the total dataset) were imputed using
trimmed scored regression (Folch-Fortuny et al., 2016) using the
partial dataset of that participant as predictors. All statistical and
imaging analysis was performed inMATLAB 2018b (MathWorks,
USA) apart from ANOVA and chi-squared tests, which were per-
formed in JASP (version 0.9.2).
Data availability
Anonymized data are available on reasonable request for aca-
demic (non-commercial) purposes, although restrictions may
apply to adhere to participant consent and anonymity.
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Results
A detailed epidemiological assessment of FTLD syndromes
in the study area has previously been reported (Coyle-
Gilchrist et al., 2016). Further demographic details of the
study cohort, including the later recruitment period, are
shown in Table 1.
We assessed in person 85% (310/365) of the patients iden-
tified as living in the study catchment area with a FTLD syn-
drome. Fifty-eight patients had a diagnosis of definite FTLD,
either by subsequent post-mortem pathological diagnosis
(n = 49) or a causative genetic mutation on clinical genetics
tests. Neuropathology details of the cohort are given in the
Supplementary material.
Sixty-two per cent (n = 194) met core diagnostic criteria
for more than one syndrome, with patients meeting the in-
clusion criteria for two (n = 112), three (n = 69) or four
(n = 13) diagnoses (Fig. 1C and D). The most commonly
overlapping syndromes were PSP and CBS (n = 76), bvFTD
and either PSP (n = 60) or svPPA (n = 38), and nfvPPA with
either CBS (n = 56) or PSP (n = 51).
We used cluster analysis to investigate how closely clinical
features related to each other. Multidimensional scaling of
clinical features (across all patients) broadly recapitulated the
phenotypic clustering as represented by the classical pheno-
types of each syndrome (Fig. 3). However, there were also
many close links between signs conventionally associated
with distinct diagnoses. For example, progressive behavioural
change, apathy, inertia and impulsivity (typical of bvFTD),
were close to symmetrical parkinsonism, falls, axial rigidity
and a supranuclear gaze palsy (typical of PSP). Other features
suggestive of bvFTD (socially inappropriate and compulsive
behaviour and stereotypy of speech), were close to features
typical of svPPA features (impaired naming, single word
comprehension and object recognition). PSP and CBS fea-
tures were closely linked, while speech apraxia, agrammatism
and impaired syntactic comprehension (indicative of nfvPPA)
overlapped with limb apraxia (indicative of CBS).
Figure 2 Schematic of data processing. First, patients were recruited from the study catchment area for phenotypic assessment and struc-
tural brain imaging. Second, a cluster analysis was performed on clinical features. Third, we performed PCA on all clinical features to find latent
syndrome dimensions across FTLD. Fourth, we used source-based morphometry (independent component analysis on grey and white matter) to
create atrophy components. Finally, we explored the relationship between phenotype (syndrome dimensions from the PCA) and brain structure
(source-based morphometry imaging components) using canonical correlation analysis. A = anterior; L = left; P = posterior; R = right.
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First, we sought latent syndromic dimensions using PCA
of the phenotypic data. Six principal components were iden-
tified using Cattell’s criteria, each representing a group of
covarying features encompassing symptoms, signs, ACE-R
and CBI-R scores (varimax-rotated component matrix in the
Supplementary material). These six components explained
58.52% of the variance in the dataset (Kaiser-Meyer-Olkin
= 0.86). Syndrome dimension 1 (Fig. 4A) reflected clinician
and carer ratings of behaviour and personality change, with
executive dysfunction, impulsivity and disinhibition, loss of
empathy, stereotyped behaviours, hyperorality and dietary
change, apathy, endorsements of abnormal behaviour,
altered eating habits and stereotypic and motor behaviour
subscales. This ‘behaviour’ dimension was expressed strong-
ly by patients with bvFTD, but also a high proportion of
PSP, CBS and svPPA patients. Some patients in these latter
groups had weightings similar to bvFTD. Syndrome dimen-
sion 2 (Fig. 4B) reflected global cognitive function, with
negative loadings from ACE-R subscores. Carer ratings of
everyday function and memory also had positive loading
onto this dimension (higher CBI-R score, reflecting greater
impairment). There was wide variation in this dimension’s
weighting across all groups, with higher scores reflecting
worse cognitive impairment.
Dimension 3 (Fig. 4C) reflected axial rigidity, postural in-
stability and a supranuclear gaze palsy (positive loading) in
the absence semantic language impairments (negative load-
ing). Thus, patients with typical PSP and typical svPPA lie at
opposite ends of this dimension, with high and low scores,
respectively. However other groups had a spread of scores,
many patients with CBS had very high scores (PSP-like).
Some bvFTD had high scores indicating a PSP-overlap, while
others had low scores, implying presence of semantic
impairment.
Positive scores on syndrome dimension 4 (Fig. 4D) repre-
sented asymmetrical parkinsonism, dystonia and myoclonus
with cortical features of apraxia, cortical sensory loss and
alien limb syndrome. Patients with CBS and a subset of
patients with PSP had high scores in this dimension.
Dimension 5 (Fig. 4E) represented language impairments
typified by agrammatic, apraxic and logopenic speech with
motor features (myoclonus and limb apraxia). Patients with
CBS, nfvPPA, logopenic variant and mixed PPA had high
weighting on this dimension, as did a small subset of those
with clinical diagnoses of PSP and bvFTD. Finally, dimen-
sion 6 explained less variance than the other components
and represented primarily carer ratings of mood and abnor-
mal beliefs (Fig. 4F). The distribution of neuropathologi-
cally-confirmed cases is shown in the Supplementary
material, section 5.
Second, we investigated the structural changes associated
with FTLD, and their associations with the clinically orien-
tated syndromic dimensions. The scanned subset of partici-
pants was similar to the population without a scan, with no
statistically significant differences in age (t = 0.65, P = 0.52),
sex (v2 = 2.8, P = 0.1), disease duration (t = 0.69, P = 0.49)
or scores on syndrome dimensions 1–3, 5 and 6 (all
P4 0.05 uncorrected). A difference in syndrome dimension
4 (t = 2.41, P = 0.02) indicated less severe global cognitive
impairment in those who were scanned. Source-based
morphometry revealed 15 significant structural components,
each representing a pattern of covarying atrophy (Fig. 5 and
Supplementary material). The components had high stability
across 100 ICASSO runs (mean = 0.981, standard deviation
Figure 3 Cluster analysis and multidimensional scaling of behavioural, language and motor impairments in FTLD. Each feature
is colour-coded by FTLD subtype (same colour codes as Fig. 1) based on the primary diagnostic criteria to which the symptom contributes. The
size of each point is scaled based on its prevalence in the cohort (larger icons have a higher prevalence). Symptoms from each FTLD syndrome
cluster together, but many features are also closely located to those from other syndromes.
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Figure 4 Principal component analysis scores of clinical features in FTLD syndromes. Six principal components (A–F) were
selected. (A) Syndrome dimension 1: clinician and carer ratings of behavioural impairment. (B) Syndrome dimension 2: global cognitive impair-
ment, composed of all ACE-R subscores. (C) Syndrome dimension 3: supranuclear gaze palsy, postural stability and symmetrical rigidity (positive
loading) and semantic language impairment (negative loading). (D) Syndrome dimension 4: asymmetrical parkinsonism, dystonia, myoclonus with
limb apraxia, cortical sensory loss and alien limb syndrome. (E) Syndrome dimension 5: agrammatic, apraxic and logopenic language impairments.
(F) Syndrome dimension 6: carer ratings of low mood and abnormal beliefs.
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Figure 5 Source-based morphometry (based on independent component analysis) of combined grey and white matter. A sub-
set of components is shown (all components are provided in the Supplementary material). Fifteen components were selected, each representing
a region of independently covarying grey and white matter atrophy. Images are standardized group spatial maps for each component, superim-
posed on an average of all brain images. The scatter-box plots show the standardized subject loading coefficients, grouped by FTLD syndrome
subtype.
1562 | BRAIN 2020: 143; 1555–1571 A. G. Murley et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/143/5/1555/5841762 by U
niversity of C
am
bridge user on 10 June 2020
= 0.004). The loadings on these imaging components were
not confined to single diagnostic groups.
Imaging components 1 and 2 related to the frontal and
prefrontal cortex; patients with bvFTD tended to have low
scores on these components (i.e. atrophy), but many patients
with nfvPPA, PSP and CBS also had low scores indicating a
frontal cortical atrophy (Fig. 5). Component 3, with bitem-
poral atrophy, had very strong negative scores in all svPPA
patients, but also many bvFTD patients. Some participants
with CBS, nfvPPA and PPA had negative scores on imaging
component 8, which reflected biparietal atrophy. Imaging
component 13 represented the volumes of corticospinal
tracts and basal ganglia. Many patients with PSP, but also
some patients with bvFTD, CBS and nfvPPA had low scores
on this component. Component 14 represented brainstem
atrophy, with large negative scores in PSP and CBS but also
some nfvPPA patients. The distribution of neuropathologi-
cally-confirmed cases is shown in the Supplementary mater-
ial, section 6.
Third, we looked for structure-function correlations be-
tween the clinical and imaging components, in the subset of
participants with MRI. As both cognition and atrophy are
intrinsically multivariate, we used canonical correlation ana-
lysis between the six cognitive dimension and 15 atrophy
components. Three canonical correlations were selected for
further analysis (each P5 0.05, rejecting the null hypothesis
that the canonical correlation is zero). The first canonical
correlation (R = 0.81, P5 0.001) represented the association
between motor impairments (syndrome dimensions 3 and 4)
and relatively preserved cognition (syndrome dimension 2)
Table 1 Demographics of the study cohort
All FTLD bvFTD nfvPPA svPPA PPA (lv
or mixed)
PSP (all) CBS P-value
Total in catchment area, n 365 81 40 28 16a 123 77 –
Clinical phenotyping n (% of
total population)
310 (85) 64 (79) 36 (93) 25 (89) 16 (100) 101 (82) 68 (88) ns*
Age, years, mean (SD) 70.26 (8.57) 64.59 (9.56) 72.09 (8.81) 67.55 (6.43) 70.80 (7.05) 72.56 (7.14) 72.08 (7.69) 50.001
Male/female 152/158 33/31 15/21 14/11 7/9 56/45 27/41 ns
Duration of symptoms, years,
mean (SD)
4.75 (3.18) 5.70 (4.45) 2.83 (1.93) 4.96 (2.69) 2.76 (1.97) 4.50 (2.94) 4.71 (2.77) ns
Time from diagnosis to study
review, mean (SD)
1.44 (2.77) 1.88 (3.88) 1.09 (1.27) 1.65 (2.01) 1.58 (1.67) 1.02 (1.17) 1.73 (2.02) ns
MRI scan (% of phenotyped patients) 133 (43) 28 (44) 15 (41) 5 (20) 10 (62) 53 (52) 22 (32) ns**
alvPPA n = 7, mixed PPA n = 9.
P-values are the result of ANOVA or v2 test for each row on FTLD subgroups: ns = not significant (P4 0.05); *ANOVA of percentage of total population in each group; **ANOVA
of percentage of phenotyped patients in each group.
Figure 6 Structure-phenotype associations using canonical correlation analysis with phenotypic (syndrome dimensions from
PCA) and structural (atrophy components from source-based morphometry) information. Three canonical correlation compo-
nents were selected, each composed of multiple imaging and clinical phenotype components. (A) First canonical correlation. Atrophy in the
motor cortex and brainstem had the greatest loading onto the imaging component. Syndrome dimensions 3 (PSP-like motor features) and 4
(CBS-like motor features) had positive loadings and syndrome dimension 2 (global cognitive impairment) had negative loading on the clinical com-
ponent. (B) Second canonical correlation. Atrophy in the frontal and temporal lobes had the greatest loading on the imaging component. On the
clinical component, syndrome dimension one (behavioural impairment) had positive loadings. (C) Third canonical correlation. A spread of cor-
tical and subcortical atrophy components loaded on the imaging component and syndrome dimensions 1–3 contributed to the clinical compo-
nent. Plots of loadings onto all imaging and clinical components are provided in the Supplementary material.
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with motor cortex and brainstem atrophy (atrophy compo-
nents 6 and 14). Patients with PSP, CBS and some patients
with bvFTD had positive loadings, while patients with PPA
(notably the svPPA subtype) and some with bvFTD had
negative loadings (Fig. 6A). Four of six FTLD subgroups
had significant correlations in this canonical correlation: PSP
(Pearson’s R = 0.33, P = 0.03), CBS (R = 0.81 P5 0.001),
bvFTD (R = 0.70 P5 0.001) and nfvPPA (R = 0.75
P = 0.03) (all results are provided in Supplementary material,
section 4).
The second canonical correlation (R = 0.71, P50.001)
represented another spectrum of cognitive and motor pheno-
types correlating with a different pattern of atrophy
(Fig. 6B). Positive loadings (most common in bvFTD, svPPA
and some PSP) linked behavioural impairment (syndrome di-
mension 1) with atrophy in the frontal and temporal lobes
(atrophy components 1 and 3). Negative loadings (most
common in CBS, nfvPPA and mixed PPA) linked global cog-
nitive impairment, apraxia, cortical sensory loss and lan-
guage impairments with atrophy in the parietal cortex
(atrophy components 7 and 8); bvFTD (R = 0.49, P = 0.02),
nfvPPA (R = 0.79 P = 0.001) and CBS (R = 0.7, P = 0.001)
most contributed to this canonical variate.
The third canonical correlation (R = 0.58 P5 0.001) rep-
resented a combination of behavioural, cognitive and motor
symptoms in association with atrophy in motor and parietal
cortices, basal ganglia and brainstem (Fig. 6C). This canon-
ical correlation had positive loadings across a wide range of
diagnoses. This canonical correlation was driven by CBS
(R = 0.62 P = 0.005), PSP (R = 0.54 P5 0.001) and PPA
(R = 0.87 P = 0.003) subgroups with a weaker contribution
from svPPA (R = 0.91, P = 0.048), nfvPPA (R = 0.54,
P = 0.06) and bvFTD (R = 0.37, P = 0.07). The three re-
sidual, unselected canonical covariates did not correlate in
any FTLD subgroup. The distribution of neuropathologi-
cally confirmed cases is shown in the Supplementary mater-
ial, section 7.
The final analysis considered the longitudinal change in
the 46 patients who were alive and assessed in both 2013–
14 and 2017–18. The mean time between assessments was
3.6 years (standard deviation 0.87 years). At baseline,
patients with follow-up were younger (mean 67.0 versus
70.9, t = 2.8, P = 0.005) but had similar sex ratio and dis-
ease duration to those without follow-up. Patients with fol-
low-up had lower scores on syndrome dimension 3
(t = 3.55, P50.001), with fewer PSP cases (v2 = 3.94,
P50.05). The other five dimension scores at baseline were
not different between patients with and without follow-up.
Between first and second assessments there was progression
in all syndrome dimensions across all groups. At the second
assessment there was greater overlap between diagnostic
groups, across all syndrome dimensions (Fig. 7). More
patients met two or more sets of diagnostic criteria (after
removing mutual exclusivity criteria) at follow-up (n = 42)
compared to baseline (n = 33) (v2 with Yates correction =
4.618, P = 0.031).
Discussion
Using a data-driven analysis of cross-sectional phenotypes,
this epidemiologically-based study revealed that the common
syndromes associated with FTLD are not discrete in their
clinical features or structural brain changes (Fig. 1A), but in-
stead exist as a multidimensional spectrum (Fig. 1B). Many
patients displayed the diagnostic features for multiple diag-
noses (Fig. 1C and D). The dimensions of behaviour, move-
ment and language features occurred to varying degrees
across all the major diagnostic groups. Differences between
groups were expressed by different weightings along these
spectra, rather than by categorical clinical or imaging
features.
Despite the continuity among patient phenotypes, the clin-
ical syndromes are not random associations. There were
close associations between sets of cognitive, behavioural,
language and motor features, which are reminiscent of the
classical phenotypes (Fig. 2). For example, syndrome dimen-
sion 3 represents supranuclear gaze palsy, falls, akinesia and
preserved semantics, typical of PSP-Richardson’s syndrome.
However, 44% of CBS patients expressed this pattern to the
same degree as PSP patients. The recognition of such overlap
has contributed to the development of intermediate diagno-
ses like PSP-CBS (Ho¨glinger et al., 2017) and CBS-PSP
(Armstrong et al., 2013) but our results indicate that such
overlap is common rather than exceptional. However, not
all potential intermediate phenotypes occur. For example, a
supranuclear gaze palsy, axial and symmetrical limb rigidity
rarely coexist with semantic impairment, a combination that
has been reported only in exceptional cases of mixed tau
and TDP43 pathology (Snowden et al., 2019).
We propose that a spectral approach is critical to under-
stand the biological basis of the complex clinical syndromes,
and to target future therapies appropriately. Rather than
focus on the determinants of disease or treatment by diagno-
sis, one can focus on the determinants and treatment of the
syndromic dimensions, in whichever diagnostic ‘group’ these
dimensions are expressed. To do otherwise risks the misdir-
ection of a treatment or the dilution of the effects of aetio-
logical factors, whether genetic, environmental, or aggregate
of pathogenic proteins. In other words, one could under-
stand and potentially treat the ‘PSP-like’ features whether
they occurred in the context of clinically diagnosed PSP-
Richardson’s syndrome, CBS or bvFTD.
We do not suggest that the current diagnostic criteria are
invalid. Instead, our results highlight the limitations of a cat-
egorical approach to diagnosis when the disorders are inher-
ently multivariate spectra in their clinical and imaging
features. Nor do our data suggest incorrect diagnosis: al-
though only 49 of the patients have had post-mortem exam-
ination, the results confirmed clinicopathological
correlations in keeping with the literature [very high for PSP
(Gazzina et al., 2019) and svPPA (Spinelli et al., 2017), pre-
dominantly corticobasal degeneration or Alzheimer’s disease
pathologies for CBS (Alexander et al., 2014), and either tau
or TDP43 pathologies for bvFTD (Perry et al., 2017)].
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Indeed, the symptom-based data-driven cluster analysis
broadly reproduced the diagnostic criteria. But, the relative
weightings on such clusters were graded, which highlights
the difficulties when applying diagnostic criteria to patients
with intermediate or mixed phenotypes (Spinelli et al.,
2017).
Our analysis did not differentiate features that are more
salient to a clinician (e.g. supranuclear gaze palsy) from
those that are more salient to a relative or carer (e.g. behav-
ioural disturbance, non-fluent aphasia or falls). This differ-
ence in perspective is relevant to diagnostic labelling. For
example, a patient with apraxia, akinesia, dystonia and non-
fluent agrammatic speech might be diagnosed as CBS or
nfvPPA according to the dominant clinical features: but
whose opinion on dominance matters most, the patient,
carer or clinician? This is complicated further by the change
in insight associated with many FTLD syndromes (O’Keeffe
et al., 2007). A further complication for the categorical ap-
proach to diagnosis is the evolution of behavioural, motor
or language features over time, which raises the question of
whether the diagnosis label should be changed or comple-
mented by a secondary, parallel diagnosis. Our approach
largely resolves this issue by taking a transdiagnostic ap-
proach based on clinical and/or imaging domains, which we
consider below.
The data-driven approach identified close clustering of the
clinical features and six latent syndrome dimensions that
demonstrated the high degree of overlap across FTLD syn-
dromes. Behavioural features were closely clustered and
loaded onto one syndrome dimension. However, they also
clustered near cognitive and motor symptoms/signs. Apathy
and impulsivity had a close link, reflecting the fact that they
often coexist, rather than representing opposite ends of a
hyper-hypo-kinetic spectrum (Lansdall et al., 2017). Many
patients had apathy, which lay near the centre of the multi-
dimensional scaling plot (Fig. 3), suggesting that it is related
similarly to other features across FTLD syndromes. The be-
havioural syndrome dimension was expressed across mul-
tiple groups and was not restricted to the subset of the
cohort with bvFTD (Fig. 4A). Furthermore, not all patients
with bvFTD had very high scores on this behavioural syn-
drome dimension. Those with lower behaviour scores, but a
clinical diagnosis of bvFTD, may represent bvFTD with
prominent apathetic/dysexecutive symptoms (O’Connor
et al., 2017), or reflect more advanced disease when some of
the more florid behavioural changes are less pronounced
(O’Connor et al., 2016). Many patients with PSP and CBS
had high scores on this syndrome dimension. Behavioural
changes in PSP and CBS are well recognized (Burrell et al.,
2014), but are often thought to be mild. Our findings
Figure 7 Longitudinal phenotype information. A subset of patients was assessed at two time points. Three arbitrary pairs of syndrome
dimensions are given to illustrate the convergence of clinical phenotype in syndrome dimensions at follow-up. Each ellipse shows the 95% confi-
dence intervals of the syndrome dimension scores for each FTLD subgroup at baseline and follow-up. At follow-up there was greater overlap
across all FTLD syndromes in all syndrome dimensions.
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suggest that behavioural impairments in PSP and CBS can
be prominent: some patients with PSP and CBS had higher
scores on this syndrome dimension than patients with
bvFTD. Behavioural features coexisted with all other FTLD-
related features. Global cognitive impairment was repre-
sented by syndrome dimension 2. The ACE-R subscores and
carer ratings of everyday skills and memory loaded onto this
dimension. However, the reasons for low ACE-R scores may
vary depending on which other symptom profiles are
expressed: a low score on the ACE-R could be due to pro-
gressive dementia or caused by severe behavioural (syn-
drome dimension 1) or language (dimension 5) or motor
(dimensions 3 and 4) impairment, all of which would inter-
fere with the test session.
Our results are also relevant to the current nosology of
primary progressive aphasias. Semantic impairments loaded
onto a different syndrome dimension and clustered separate-
ly from the language impairments associated with nfvPPA
and lvPPA. This provides partial support for the current dis-
tinction between svPPA and other forms of PPA. However,
nfvPPA and lvPPA were not readily distinguished by the
data-driven analysis—as has been noted in a previous inde-
pendent cohort (Sajjadi et al., 2012). In contrast, patients
with svPPA were similar to bvFTD in many respects (Fig. 4).
Compulsive behaviours, stereotyped speech and simple re-
petitive habits were closely linked to semantic language
impairments, including object recognition and single word
comprehension (Harris et al., 2016). Other language fea-
tures, including impaired syntactic comprehension, agram-
matism and speech apraxia, were closely related to CBS-like
motor features (syndrome dimension 3), in CBS, PSP, and
nfvPPA groups—in keeping with the well characterized over-
lap of non-fluent (Rohrer et al., 2010a, b) and apraxic
(Josephs et al., 2006, 2012) speech with PSP and CBS
(Armstrong et al., 2013; Respondek and Ho¨glinger, 2016;
Peterson et al., 2019). The PPA diagnostic criteria require
that language impairments are the most prominent clinical
feature and the principal cause of difficulty with activities of
daily living. This may not be the case in some patients with
svPPA; although clinicians may note prominent semantic
impairments, coexistent behavioural impairment may be
more conspicuous to relatives or carers and have a greater
impact on independence and daily living. In addition, we re-
port the practical difficulties applying the current PPA diag-
nostic criteria. In our epidemiological-based cohort, 19
patients met criteria for primary progressive aphasia
(Gorno-Tempini et al., 2011) but not one of the PPA sub-
types. The current diagnostic criteria are stringent and re-
quire the presence and absence of multiple language
features. Patients with language symptoms may have very
isolated deficits (Josephs et al., 2012) or at the other extreme
multiple impairments which span more than one PPA sub-
type, even at diagnosis (Utianski et al., 2019).
Many studies have correlated clinical syndromes with
structural change, using computational morphometry on
volume, thickness, curvature or cortical diffusivity.
Typically, these compare patient groups to each other or to
controls, to reveal group-based patterns of atrophy in
bvFTD (Schroeter et al., 2007; Whitwell et al., 2012;
Ranasinghe et al., 2016b; Meeter et al., 2017; Perry et al.,
2017; Chen et al., 2018b; Illa´n-Gala et al., 2019), svPPA
(Gorno-Tempini et al., 2004; Schroeter et al., 2007; Kumfor
et al., 2016), nfvPPA (Gorno-Tempini et al., 2004; Schroeter
et al., 2007; Santos-Santos et al., 2016), PSP (Brenneis et al.,
2004; Lagarde et al., 2013; Piattella et al., 2015; Dutt et al.,
2016; Whitwell et al., 2017a, 2019) and CBS (Josephs et al.,
2010; Whitwell et al., 2010; Dutt et al., 2016). However,
these previous methods are limited by the categorical ap-
proach to diagnosis. To reveal the associations between
phenotypic features and structural change, across diagnostic
groups, we used source-based morphometry to identify
regions of covarying atrophy patterns (Xu et al., 2009). We
confirmed our hypothesis that individual atrophy patterns
are not confined to specific diagnostic groups. Our imaging
cohort was generally representative of the whole FTLD
population, with similar weightings across five of six dimen-
sions and demographics. Participants who underwent MRI
were less affected in the global cognitive impairment syn-
drome dimension, likely due to the practical difficulties of
scanning participants with advanced dementia. Frontal lobe
atrophy patterns were seen in participants from all groups,
especially bvFTD and PSP. Subcortical atrophy was more
prevalent in PSP and CBS but was also seen in bvFTD and
PPA, and a majority of bvFTD patients had negative scores
on the basal ganglia imaging component. This has been
noted previously in symptomatic bvFTD and PPA (Schroeter
et al., 2007; Bocchetta et al., 2018), and those at genetic risk
of FTD (Rohrer et al., 2015). Brainstem atrophy, while char-
acteristic of PSP (Whitwell et al., 2017a), was also seen in
some patients with CBS and nfvPPA, but this has previously
been shown not to predict PSP pathology (Whitwell et al.,
2013). The source-based morphometry approach also
revealed a group of patients who are not well accommo-
dated in the current diagnostic criteria. Five patients with a
nominal diagnosis of bvFTD had very low scores on the
right temporal lobe imaging component, and we suggest that
these might better be called the right variant of semantic de-
mentia, which causes a combination of behavioural and se-
mantic impairments with prosopagnosia (Chan et al., 2009;
Kumfor et al., 2016). A subset of patients with CBS and
mixed PPA had negative scores on component 8, indicating
posterior cortical atrophy. These patients may be more likely
to have Alzheimer’s disease pathology (Lee et al., 2011).
We identified three significant canonical ‘structure-func-
tion’ correlations in the cohort (Fig. 6). These represent the
spectrums of anatomical change underlying behavioural,
motor and language impairments. These structure-function
correlations did not replicate classical nosological distinc-
tions. Instead they provide an alternative data-driven ap-
proach with which to understand and target treatments for
syndromes associated with FTLD. The first canonical correl-
ation found an association between motor cortex and brain-
stem atrophy with PSP or CBS-like motor impairments.
Unsurprisingly, PSP and CBS had significant correlations
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between these canonical covariates but so did bvFTD and
nfvPPA, reflecting the motor impairments that are seen in a
subgroup of these patients. The second canonical correlation
represented the spectrum between frontotemporal (positive
scores) and posterior cortical atrophy (negative scores). This
canonical covariate may differentiate FTLD from
Alzheimer’s disease pathology, as negative scores on this
imaging covariate resemble an Alzheimer’s disease-like atro-
phy pattern (Supplementary material, section 7). The third
canonical covariate was associated with significant correla-
tions in all FTLD subgroups apart from bvFTD, and encom-
passed a range of cognitive, behaviour and motor clinical
features associated with cortical and subcortical atrophy.
Longitudinal analysis in a subset of patients confirmed
that, with disease progression, overlap between FTLD phe-
notypes increases (Kertesz et al., 2005). A greater number of
patients met criteria for several FTLD subtypes compared to
first assessment and there was greater overlap between all
syndrome dimensions (Fig. 7). Our transdiagnostic approach
allows disease progression to be more accurately repre-
sented, in terms of worsening clinical features rather than
conflicting diagnoses. Assessing FTLD syndromes in isola-
tion, without reference to the whole FTLD syndrome spec-
trum, risks missing evolving signs of other FTLD syndromes
and therefore underestimating disease severity. The time be-
tween the two phenotypic assessments was relatively long
(mean 3.6 years) given the mean survival in FTLD syn-
dromes (Coyle-Gilchrist et al., 2016). We acknowledge that
the longitudinal analysis may be biased towards patients
with slowly progressive disease (i.e. survivors over the assess-
ment interval). Indeed, patients with follow-up were younger
than those without and included fewer with PSP, which on
average has a worse prognosis than other FTLD syndromes
(Lansdall et al., 2019).
A strength of our analysis is that it is embedded within an
epidemiological cohort study with multi-source identification
and recruitment. Previous structure-function studies of these
disorders may have been influenced by low sample sizes and
selection bias, by focusing only on patients at earlier disease
stages who are well enough to attend subspecialist research
centres for detailed phenotypic assessment. The representa-
tiveness in our study may partly explain why many of our
patients overlapped diagnostic criteria.
Our study also has several limitations. Applying mul-
tiple diagnostic criteria across all patients raises challenges.
For example, the criteria often incorporate an exclusion
clause, that the illness is ‘not better explained by another
diagnosis’. We lifted this criterion and applied the clinical
features to the other positive and negative criteria. Patients
may have symptoms or signs that do not quite reach the
threshold needed to meet a diagnostic criterion. Our ap-
proach was to try to apply the same threshold in all groups,
in asserting the presence of a symptom or sign. We included
continuous measures of cognitive (ACE-R) and behavioural
(CBI-R) but not motor symptoms’ severity. Severity scales
for parkinsonism may be weighted towards specific illnesses
(e.g. the PSP-rating scale for PSP-Richardson’s syndrome),
which might bias the weighting of the motor syndrome
dimensions across FTLD subtypes. We therefore focused on
the presence, not severity, of individual symptoms, noting
that the diagnostic criteria also do not operationalize sever-
ity. We also grouped together language features for the PCA
(e.g. apraxic and agrammatic speech), which may have
made it more difficult to distinguish motor-only PPA sub-
types, noting that our a priori grouping was supported post
hoc by the data-driven cluster analysis. Our assessment of
clinical features was cross-sectional, rather than a retrospect-
ive estimate of presenting features. Some of the diagnostic
criteria (e.g. for PPA, Gorno-Tempini et al., 2011) refer to
the dominance of a symptom cluster (e.g. language disorder)
at presentation. This sounds straightforward, but the time of
presentation varies widely, is often late (Coyle-Gilchrist
et al., 2016), and is partially dependent on variations in
healthcare services, referral pathways and public awareness
of symptoms’ significance (Bradford et al., 2009). These fac-
tors interfere with the ability of symptomatology to inform
the diagnosis and likely pathology, especially in overlap syn-
dromes such as CBS-NAV (non-fluent/agrammatic variant),
or PSP-F. This transdiagnostic approach to FTLD may not
be appropriate in all situations, for example trials of treat-
ments targeting a specific proteinopathy. Robust biomarkers
that can differentiate between, for example FTLD-tau and
FTLD-TDP43, are thus far lacking (Bevan-Jones et al.,
2017; Meeter et al., 2017). Currently, trials focus recruit-
ment on subsets of patients with strong clinicopathological
correlation such as PSP-Richardson’s syndrome (Boxer et al.,
2019). However, this limits patient access to drug trials,
given the poor clinicopathological correlation in many
FTLD syndromes. More accurate biomarkers, whether PET,
CSF or blood-based (Meeter et al., 2017; Leuzy et al.,
2019), would facilitate transdiagnostic approaches and ac-
curate drug targeting while maximizing power and generaliz-
ability of results. A further limitation is the small number to
date with post-mortem confirmation of pathology. As set
out in the Supplementary material, the 49 neuropathological
results are in line with the literature for each syndrome, but
with only 21 of the 49 also having MRI, there was insuffi-
cient power for predictive models of pathology.
Research related to disease nosology often raises the
issue of whether to ‘lump’ disorders together or to ‘split’
them into subtypes (Scaravilli et al., 2005). The decision to
lump or split can reveal insights into the neurobiology of dis-
ease. But, lumping and splitting can also obscure insights.
We propose an alternative approach, with data-driven spec-
tral analyses, that neither lump nor split arbitrarily, but
allow phenotypic and imaging variance to elucidate patho-
genesis of cognitive syndromes. We acknowledge that our
brain metrics are only crude measures of atrophy. Other
brain measures, of tau burden (Passamonti et al., 2017;
Whitwell et al., 2017b; Bevan-Jones et al., 2020), synaptic
density (Chen et al., 2018a), physiology (Hughes et al.,
2018; Sami et al., 2018) and functional connectivity (Seeley
et al., 2009; Rittman et al., 2019) may enrich the source-
based morphometric approach, integrating PET markers of
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pathology (Passamonti et al., 2019) or spectroscopic meas-
ures of the neurotransmitter deficits in FTLD (Kantarci
et al., 2010; Murley and Rowe, 2018). Genetic information
could further inform the multivariate analysis of phenotype,
mindful that while bvFTD has a strong genetic component,
svPPA and PSP do not (Rohrer et al., 2009). An additional
limitation is the potential for multiple pathologies, in which
several pathogenic protein inclusions may coexist and be
synergistic in neurodegeneration (Robinson et al., 2018).
In conclusion, we have presented evidence from a trans-
diagnostic, data-driven approach to the clinical and struc-
tural phenotypes in syndromes associated with FTLD.
Patient categorization and selection should depend on the
study or question of interest (Husain, 2017; Coulthard and
Love, 2018), but for understanding the origin of symptoms,
designing symptomatic treatment, and assessment of diag-
nostic biomarkers, we suggest that the more relevant out-
comes are the data-driven axes of disease. Clinical
heterogeneity and phenotypic variance are ‘noise’ in cat-
egory-based analysis of disease and treatment effects, and
undermine the observation of effects. However, the same
variance can be informative in terms of a spectrum of struc-
ture-function abnormality, complementing data-driven
approaches to characterize neurodegenerative disease using
neuropathological features (Cornblath et al., 2019). The
data-driven approach provides a comprehensive framework
with which to understand disease progression and hetero-
geneity, and guide treatment.
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